Journal of Molecular and Cellular Cardiology
Volume 49, Issue 6 , Pages 1031-1041 , December 2010

A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex

  • Ian M. Robertson

      Affiliations

    • Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    • ,
  • Yin-Biao Sun

      Affiliations

    • Randall Division of Cell and Molecular Biophysics, King's College London, London, SE1 1UL, UK
    • ,
  • Monica X. Li

      Affiliations

    • Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    • ,
  • Brian D. Sykes

      Affiliations

    • Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
    • Corresponding Author InformationCorresponding author. Tel.: +1 780 492 5460; fax: +1 780 492 0886.

Received 13 July 2010 ,Revised 17 August 2010 ,Accepted 19 August 2010.

References 

  1. Li MX, Wang X, Sykes BD. Structural based insights into the role of troponin in cardiac muscle pathophysiology. J Muscle Res Cell Motil. 2004;25:559–579
  2. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog Cardiovasc Dis. 2004;47:159–176
  3. Gomes AV, Potter JD, Szczesna-Cordary D. The role of troponins in muscle contraction. IUBMB Life. 2002;54:323–333
  4. Endoh M. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?. Br J Pharmacol. 2007;150:826–828
  5. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305–315
  6. Li MX, Robertson IM, Sykes BD. Interaction of cardiac troponin with cardiotonic drugs: a structural perspective. Biochem Biophys Res Commun. 2008;369:88–99
  7. Haikala H, Nissinen E, Etemadzadeh E, Linden IB, Pohto P. Levosimendan increases calcium sensitivity without enhancing myosin ATPase activity and impairing relaxation. J Mol Cell Cardiol. 1992;24(Suppl 5):S97
  8. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin-C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859–1866
  9. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794–801
  10. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem. 2004;266:87–107
  11. Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundstrom K, Kalkkinen N, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin-C — a molecular modeling, fluorescence probe, and proton nuclear-magnetic-resonance study. J Biol Chem. 1994;18(269):28584–28590
  12. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337–9343
  13. Li MX, Saude EJ, Wang X, Pearlstone JR, Smillie LB, Sykes BD. Kinetic studies of calcium and cardiac troponin I peptide binding to human cardiac troponin C using NMR spectroscopy. Eur Biophys J Biophys Lett. 2002;31:245–256
  14. M.J. Frisch GWT, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, J. A. Montgomery, Jr., T. et al. Gaussian 03. Gaussian 03 ed. Wallingford CT: Gaussian, Inc. 2004.
  15. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–2791
  16. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity — a rapid access to atomic charges. Tetrahedron. 1980;36:3219–3228
  17. Li Y, Love ML, Putkey JA, Cohen C. Bepridil opens the regulatory N-terminal lobe of cardiac troponin C. Proc Natl Acad Sci USA. 2000;97:5140–5145
  18. Gemmecker G, Olejniczak ET, Fesik SW. An improved method for selectively observing protons attached to 12C in the presence of 1H–13C spin pairs. J Magn Reson. 1992;96:199–204
  19. Ikura M, Bax A. Isotope-filtered 2D NMR of a protein peptide complex — study of a skeletal–muscle myosin light chain kinase fragment bound to calmodulin. J Am Chem Soc. 1992;114:2433–2440
  20. Ogura K, Terasawa H, Inagaki F. An improved double-tuned and isotope-filtered pulse scheme based on a pulsed field gradient and a wide-band inversion shaped pulse. J Biomol NMR. 1996;8:492–498
  21. Wang X, Li MX, Sykes BD. Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147–163 and bepridil. J Biol Chem. 2002;277:31124–31133
  22. Yu C, Levy GC. Solvent and intramolecular proton dipolar relaxation of the 3 phosphates of ATP — a heteronuclear 2D NOE study. J Am Chem Soc. 1983;105:6994–6996
  23. Rinaldi PL. Heteronuclear 2D-NOE spectroscopy. J Am Chem Soc. 1983;105:5167–5168
  24. Lee W, Revington MJ, Arrowsmith C, Kay LE. A pulsed-field gradient isotope-filtered 3d 13C HMQC-NOESY experiment for extracting intermolecular NOE contacts in molecular-complexes. FEBS Lett. 1994;350:87–90
  25. Robertson IM, Spyracopoulos L, Sykes BD. The evaluation of isotope editing and filtering for protein–ligand interaction elucidation by NMR. In: Biophysics and the Challenges of Emerging Threats. 2009;p. 101–119
  26. Krudy GA, Kleerekoper Q, Guo XD, Howarth JW, Solaro RJ, Rosevear PR. NMR-studies delineating spatial relationships within the cardiac troponin-I troponin-C complex. J Biol Chem. 1994;269:23731–23735
  27. Lin X, Krudy GA, Howarth J, Brito RMM, Rosevear PR, Putkey JA. Assignment and calcium-dependence of methionyl εC and εH resonances in cardiac troponin-C. Biochemistry. 1994;33:14434–14442
  28. Gariepy J, Kay LE, Kuntz ID, Sykes BD, Hodges RS. Nuclear magnetic resonance determination of metal proton distances in a synthetic calcium-binding site of rabbit skeletal troponin-C. Biochemistry. 1985;24:544–550
  29. Schuttelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004;60:1355–1363
  30. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRpipe — a multidimensional spectral processing system based on unix pipes. J Biomol NMR. 1995;6:277–293
  31. Johnson BA, Blevins RA. NMRView — a computer-program for the visualization and analysis of NMR data. J Biomol NMR. 1994;4:603–614
  32. Slupsky CM, Boyko RF, Booth VK, Sykes BD. Smartnotebook: a semi-automated approach to protein sequential NMR resonance assignments. J Biomol NMR. 2003;27:313–321
  33. Cornilescu G, Delaglio F, Bax A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR. 1999;13:289–302
  34. Guntert P. Automated NMR structure calculation with CYANA. Methods Mol Biol. 2004;278:353–378
  35. Schwieters CD, Kuszewski JJ, Clore GM. Using Xplor-NIH for NMR molecular structure determination. Prog Nucl Magn Reson Spectrosc. 2006;48:47–62
  36. Linge JP, Williams MA, Spronk CAEM, Bonvin AMJJ, Nilges M. Refinement of protein structures in explicit solvent. Proteins: Struct, Funct, Bioinf. 2003;50:496–506
  37. Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8:477–486
  38. Sun YB, Lou F, Irving M. Calcium- and myosin-dependent changes in troponin structure during activation of heart muscle. J Physiol-Lond. 2009;587:155–163
  39. Lapka R, Smolik S, Rejholec V. Pharmacokinetics of flobufen and its main active metabolite in the rat. Drug Metab Dispos. 1990;18:1060–1064
  40. Williams DE, Houpt DJ. Fluorine nonbonded potential parameters derived from crystalline perfluorocarbons. Acta Crystallogr, Sect B: Struct Sci. 1986;42:286–295
  41. Smart BE. Fluorine substituent effects (on bioactivity). J Fluorine Chem. 2001 Jun;109(1):3–11
  42. DiMagno SG, Sun HR. The strength of weak interactions: aromatic fluorine in drug design. Curr Top Med Chem. 2006;6:1473–1482
  43. Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol. 2000;32:479–491
  44. Bohm HJ, Banner D, Bendels S, Kansy M, Kuhn B, Muller K, et al. Fluorine in medicinal chemistry. Chembiochem. 2004;5:637–643
  45. Spyracopoulos L, Li MX, Sia SK, Gagne SM, Chandra M, Solaro RJ, et al. Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry. 1997;36:12138–12146
  46. McKay RT, Saltibus LF, Li MX, Sykes BD. Energetics of the induced structural change in a Ca2+ regulatory protein: Ca2+ and troponin I peptide binding to the E41A mutant of the N-domain of skeletal troponin C. Biochemistry. 2000;39:12731–12738
  47. Paakkonen K, Sorsa T, Drakenberg T, Pollesello P, Tilgmann C, Permi P, et al. Conformations of the regulatory domain of cardiac troponin C examined by residual dipolar couplings. Eur J Biochem. 2000;267:6665–6672
  48. Li MX, Spyracopoulos L, Sykes BD. Binding of cardiac troponin-I147–163 induces a structural opening in human cardiac troponin-C. Biochemistry. 1999;38:8289–8298
  49. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67–74
  50. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, et al. Effects of levosimendan, a cardiotonic agent targeted to troponin-C, on cardiac-function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic-reticulum in guinea-pig heart. Circ Res. 1995;77:107–113
  51. Sorsa T, Pollesello P, Rosevear PR, Drakenberg T, Kilpelainen L. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol. 2004;486:1–8
  52. Kleerekoper Q, Liu W, Choi D, Putkey JA. Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998;273:8153–8160
  53. Igarashi T, Takeda S, Mori H. Crystal structure of the N-terminal domain of human cardiac troponin C in complex with a calcium-sensitizer; trifluoperazine. J Mol Cell Cardiol. 2005;39:1016-
  54. Hoffman RMB, Sykes BD. Structure of the inhibitor W7 bound to the regulatory domain of cardiac troponin C. Biochemistry. 2009;48:5541–5552
  55. Robertson IM, Baryshnikova OK, Li MX, Sykes BD. Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C–troponin I complex. Biochemistry. 2008;47:7485–7495
  56. Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature. 2003;424:35–41
  57. Oleszczuk M, Robertson IM, Li MX, Sykes BD. Solution structure of the regulatory domain of human cardiac troponin C in complex with the switch region of cardiac troponin I and W7: the basis of W7 as an inhibitor of cardiac muscle contraction. J Mol Cell Cardiol. 2010;48:925–933
  58. John M, Pintacuda G, Park AY, Dixon NE, Otting G. Structure determination of protein–ligand complexes by transferred paramagnetic shifts. J Am Chem Soc. 2006;128:12910–12916
  59. Vinogradova MV, Stone DB, Malanina GG, Karatzaferi C, Cooke R, Mendelson RA, et al. Ca2+-regulated structural changes in troponin. Proc Natl Acad Sci USA. 2005;102:5038–5043
  60. Amin EN, Abdel-Alim AAM, Abdel-Moty SG, El-Shorbagi ANA, Abdel-Rahman MS. Synthesis of new 4, 5–3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities. Arch Pharmacol Res. 2010;33:25–46

PII: S0022-2828(10)00320-2

doi: 10.1016/j.yjmcc.2010.08.019

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 6 , Pages 1031-1041 , December 2010

Article Tools

* Image Usage & Resolution